• Policy
• MFDS promotes RWD analysis of COVID-19 vaccines & txs
• by Lee, Hye-Kyung May 18, 2022 05:51am

• Policy
• Discussions on the benefits of migraine txs begin in earnest
• by Lee, Tak-Sun May 16, 2022 06:14am

• Policy
• Daewoong’s P-CAB drug Fexclu receives conditional approval
• by Lee, Tak-Sun May 16, 2022 06:14am

• Policy
• MOHW holds a launching meeting of the pharmaceutical team
• by Kim, Jung-Ju May 13, 2022 05:46am

• Policy
• Vaccine consultative body launched
• by Kim, Jung-Ju May 13, 2022 05:45am

• Policy
• Will Ho-Young Chung be able to enter Cabinet?
• by Lee, Jeong-Hwan May 12, 2022 06:07am

• Policy
• Evusheld will be included in Govnt's supplementary budget
• by Lee, Jeong-Hwan May 12, 2022 06:06am

• Policy
• “Dualized RWD collection for Kymriah is inefficient”
• by Lee, Tak-Sun May 11, 2022 05:55am

• Policy
• Reblozyl was approved after 1 yr of designation of rare drug
• by Lee, Hye-Kyung May 11, 2022 05:55am

• Policy
• President Yoon said he was grateful to the people
• by Lee, Jeong-Hwan May 11, 2022 05:55am